Hematology, University of Siena, Azienda Ospedaliera Universitaria Senese, Policlinico "Santa Maria alle Scotte", Siena, Italy.
Rev Recent Clin Trials. 2022;17(1):9-10. doi: 10.2174/1574887116666211123092915.
Minimal residual disease (MRD) detection represents a great advancement in multiple myeloma. New drugs are now available that increase depth of response. The International Myeloma Working Group recommends using next-generation flow cytometry (NGF) or next-generation sequencing (NGS) to search for MRD in clinical trials. Best sensitivity thresholds have to be confirmed, as well as timing to detect it. MRD has proven as the best prognosticator in many trials and promises to enter also in clinical practice to guide future therapy.
微小残留病灶 (MRD) 的检测是多发性骨髓瘤领域的重大进展。目前有新的药物可以增加反应的深度。国际骨髓瘤工作组建议在临床试验中使用下一代流式细胞术 (NGF) 或下一代测序 (NGS) 来寻找 MRD。需要确认最佳的灵敏度阈值，以及检测的时间。MRD 在许多试验中已被证明是最佳的预后因素，并有望进入临床实践，以指导未来的治疗。
